Synonyms: GSK-2398852 | GSK2398852
Compound class:
Antibody
Comment: Dezamizumab (GSK2398852) is an anti-human serum amyloid P component (anti-SAP) monoclonal antibody, that was developed by GlaxoSmithKline as a potential therapy for the rare disease amyloidosis.
|
No information available. |
Summary of Clinical Use ![]() |
Phase 1 clinical trial NCT01777243 was completed in patients with systemic amyloidosis to assess treatment with GSK2398852 in combination with miridesap (GSK2315698, a SAP depleting chemical [1]). Development in amyloidosis was discontinued, and phase 2 study NCT03044353 was terminated. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Amyloidosis is a rare disease that results from accumulation of misfolded proteins, or amyloids. SAP stabilises amyloid fibrils and protects them from proteolytic breakdown [5]. and plays a role in the pathogenesis of systemic amyloidosis [2]. Antibodies against SAP are reported to effectively clear visceral amyloid deposits in mice by inducing a potent, complement dependent, macrophage-derived giant cell reaction [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | Phase 1 Interventional | GlaxoSmithKline | 3-4 | |
NCT03044353 | Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 | Phase 2 Interventional | GlaxoSmithKline |